Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Noxopharm Ltd. ( (AU:NOX) ).
Noxopharm Limited announced promising results from a collaboration with BioRay Pharmaceutical, which tested Noxopharm’s Sofra™ platform. The study confirmed the anti-inflammatory activity of Sofra drugs, demonstrating their potential in enhancing the performance of BioRay’s antibody for autoimmune diseases. This collaboration is part of Noxopharm’s broader strategy to explore the commercial potential of its Sofra assets through multiple international partnerships, potentially strengthening its position in the biotech industry.
More about Noxopharm Ltd.
Noxopharm Limited is an Australian clinical-stage biotech company focused on discovering and developing novel treatments for cancer and inflammation. The company is pioneering technology to improve the safety profile of mRNA medicines and leverages in-house capabilities and strategic partnerships to build a pipeline of proprietary drugs based on two technology platforms.
Average Trading Volume: 81,792
Technical Sentiment Signal: Sell
Current Market Cap: A$21.04M
See more insights into NOX stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue